Importance of race/ethnicity in clinical trials: Lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Circulation

Volumn 112, Issue 23, 2005, Pages 3654-3660

  Taylor, Anne L ^a   Wright Jr , Jackson T ^b   Cooper, Richard S ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LISINOPRIL; THIAZIDE DIURETIC AGENT;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ETHNIC GROUP; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK REDUCTION; STROKE; TREATMENT OUTCOME; METHODOLOGY; RACE; RENOVASCULAR HYPERTENSION;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY DISEASES; MYOCARDIAL INFARCTION;

EID: 33644873291     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.540443     Document Type: Article

References (55)

1. Gromann R, Ginsberg J, American College of Physicians. Racial and ethnic disparities in health care. Ann Intern Med. 2004;141:226-232.
2. Mayberry R, Boone L. Racial/Ethnic Differences in Cardiac Care: The Weight of the Evidence. Menlo Park, Calif: American College of Cardiology Foundation, Henry J. Kaiser Family Foundation; 2002. Publication No. 6041.
3. Smedley BD, Stith AY, Nelson AR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
4. Woolf SH, Johnson RE, Fryer GE Jr, Rust G, Satcher D. The health impact of resolving racial disparities: an analysis of U.S. mortality data. Am J Public Health. 2002;288:2421-2431.
5. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
6. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostland SG, for the African-American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
7. Davis BR, Cutler JA, Gordon DJ, Forberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
8. Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
9. Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro VV, Eckfeldt J, Hawkins CM, Perry HM Jr, Proschan M. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
10. Yancy CW. Heart failure in African-Americans: a cardiovascular enigma. J Card Fail. 2000;6:183-186.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
12. Johnson ER, Wright JT Jr. Management of hypertension in black populations. In: Weber MA, Oparil S, eds. Hypertension. Philadelphia, Pa: Elsevier; 2005.
13. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178-187.
14. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients [published correction appears in J Am Coll Cardiol. 2002;40:1019]. J Am Coll Cardiol. 2002;40:311-317.
15. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
16. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M, US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
17. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
18. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R. Design and baseline characteristics of participants in the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17:3S-16S.
19. US Renal Data System. 1989 Annual Report. Bethesda, Md: National Institutes of Health; 1989.
20. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998;31:1235-1239.
21. Gillum RF. Pathophysiology of hypertension in blacks and whites: a review of the basis of racial blood pressure differences. Hypertension. 1979;1:468-475.
22. Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. In: Brest AN, ed. Cardiovascular Diseases in Blacks. Philadelphia, Pa: FA Davis Co; 1991:3-16.
23. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger J, McDonald R, Lewis CE, Liebson PR, for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724.
24. Striker GE. Kidney disease and hypertension in blacks. Am J Kidney Dis. 1992;20:673.
25. Rahman M, Douglas JG, Wright JT Jr. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125-144.
26. Coresh J, Toto RD, Kirk KA, Whelton PK, Massry S, Jones C, Agodoa L, van Lente F. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study. Am J Kidney Dis. 1998;32:32-42.
27. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
28. Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol. 1995;141:10-15.
29. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R, for the AASK Pilot Study Investigators. Accuracy of the diagnosis of hypertensive nephrosclerosis in African-Americans: a report from the African-American Study of Kidney Disease (AASK) Trial. Kidney Int. 1997;51:244-252.
30. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright JT Jr; African-American Study of Hypertension and Kidney Disease. Comparison of cross-sectional renal function measurements in African-Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate [published correction appears in Am J Kidney Dis. 2002;39:444]. Am J Kidney Dis. 2001;38:744-753.
31. Lewis J, Greene T, Appel LJ, Contreras G, Douglas J, Lash J, Toto R, van Lente F, Wang X, Wright JT Jr, AASK Study Group. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African-American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2004;15:3175-3183.
32. Appel LJ, Middleton J, Miller ER III, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003;14:S166-S172.
33. World Health Organization. World Health Report 2002: Reducing Risk, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
34. Julius S, Alderman MH, Beevers G, Dahlof B, Devereaux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright JT Jr. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43:1047-1055.
35. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
36. McHutchison JB, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavarin on response to therapy in black patients with chronic hepatitis C. Gastroenterology. 2000;119:1317-1323.
37. Rajender KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Job T, for the International Hepatitis Interventional Therapy Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology. 1999;30:787-793.
38. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
39. Corbie-Smith GM. Minority recruitment and participation in health research. N C Med J. 2004;65:385-387.
40. Svensson CK. Representation of American blacks in clinical trials of new drugs. JAMA. 1989;261:263-265.
41. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolnark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
42. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829-1846.
43. Taylor AL, Adams-Campbell L, Wright JT Jr. Risk/benefit assessment of tamoxifen to prevent breast cancer: still a work in progress? J Natl Cancer Inst. 1999;91:1792-1793.
44. Taylor AL. SERMS, ethnicity, and clinical trials: opportunities and challenges. Ann N Y Acad Sci. 2001;949:292-294.
45. McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, Cronin W, Wickerham DL. Contralateral breast cancer and thromboembolic events in African-American women treated with tamoxifen. J Natl Cancer Inst. 2004;96:1762-1769.
46. NIH guidelines on the inclusion of women and minorities as subjects in clinical research, 59 Federal Register 14508-14513 (1994).
47. Pub L No. 108-155. Pediatric Research Equity Act of 2003.
48. King TE. Racial disparities in clinical trials. N Engl J Med. 2002;346:1400-1402.
49. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJP, Kazemeier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
50. Winick NJ, Carroll WL, Hunger SP. Childhood leukemia: new advances and challenges. N Engl J Med. 2004;351:601-603.
51. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
52. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850.
53. Tang H, Quertermous T, Rodriguez B, Kardia SL, Xiaofeng Z, Brown A, Pankow JS, Province MA, Hunt SC, Boerwinkle E, Schork NJ, Risch NJ. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;76:268-275.
54. Rotimi CN. Are medical and nonmedical uses of large-scale genomic markers conflating genetics and "race"? Nat Genet. 2004;36:S43-S47.
55. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet. 2004;36:S34-S42.